Printer Friendly

Bacterial decontamination reduces GVHD in patients receiving BMTs, study finds.

Bacterial decontamination with metronidazole and ciprofloxin can significantly reduce the severity of graft-versus-host disease (GVHD) in patients with hematologic malignancies receiving HLA-identical bone marrow transplants (BMT) from sibling donors, according to German researchers.

An open-label, 5-week trial in 134 BMT patients showed that combination treatment with metronidazole and ciprofloxin resulted in "...a pronounced reduction of intestinal anaerobic bacterial growth posttransplant" compared with single-drug ciprofloxin therapy, researchers at the University Hospital of Essen, Germany reported in the May 15th issue of Blood. Moreover, significantly fewer patients receiving combination therapy developed grades II to IV acute GVHD compared with those treated with ciprofloxin alone, with rates of 25% and 50%, respectively.

The benefits of bacterial decontamination were limited to patients receiving HLA-identical BMT from sibling donors, according to Dietrich Beelen, MD, and colleagues.
COPYRIGHT 1999 Transplant Communications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Bacterial decontamination reduces GVHD in patients receiving BMTs, study finds.
Publication:Transplant News
Geographic Code:1USA
Date:Jul 16, 1999
Words:131
Previous Article:50% of patients with CHF who get transplants survive at least 10 years.
Next Article:Hepatitis C-positive livers transplanted in HCV-infected patients work well.
Topics:


Related Articles
Pre-treating histoincompatible donor bone marrow reduces risk of GVHD.
Children undergoing BMTs often develop lung problems, study finds.
Gene therapy using interleukin 12 successfully treats GVHD in mice.
Children who receives BMT's may be shorter at maturity, study finds.
Patients with high-risk blood, immune system cancers survive longer with stem cell transplants than BMTs.
Umbilical cord blood alternative source for hemotopoietic stem cells for adults, study finds.
GVHD more common after peripheral stem cell transplantation than BMT.
New methods for improving mismatched BMT success rates.
Unrelated BMT can be effective for ALL in second remission.
NHLBI awards first grants in new cell-based research program for heart, lung and blood diseases.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters